Clinical Trials

Home » Research News » Clinical Trials

Video: “How clinical trials have changed prostate cancer care”

March 2018 Awareness Night How clinical trials have changed prostate cancer care   Dr. Andrew Loblaw BSc MD MSc FRCPC CIP Clinician Scientist , Ontario Association of Radiation OncologyStaff Radiation Oncologist & Clinician Scientist, Sunnybrook Health Sciences Centre Scientist, Sunnybrook Research Institute Fellow, American Society of Clinical Oncology  (ASCO) Co-Chair, GU group for Cancer Care Ontario’s Program in Evidence-Based Care Previous Co-Chair, ASCO’s Genitourinary Advisory Group Professor, Department of Radiation Oncology at University of Toronto Professor,The Institute of Health Policy, Management and Evaluation (IHPME) CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 66:27 minutes 

Almost all men with early prostate cancer survive 10 years, regardless of treatment

The survival rate for early-stage prostate cancer is 99 percent after 10 years, regardless of whether men undergo surgery, radiation or are “actively monitored,” according to studies published Wednesday. Researchers hailed the results as good news, saying they had been expecting a survival rate of 90 percent. This article is hopeful, but leaves questions.  It’s not clear how ‘early is defined or whether the arms were truly randomized.  Read the article, carefully.

Clinical trial will test use of MRI to improve prostate cancer diagnosis and management

The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective is to determine whether MRI imaging can spare some men from undergoing a biopsy and avoid the possible associated side effects. The trial will be led by Dr. Laurence Klotz of the Sunnybrook Research Institute in Toronto. Read the article.

Half of medical reporting ‘is subject to spin’

A study that you probably won’t be reading in your daily paper or favourite news website anytime soon casts serious doubts on the reliability of mainstream medical and health journalism. The study found that 51% of news items reporting on medical trials – specifically on randomised controlled trials (RCTs), which are seen as the gold standard in judging whether a treatment is effective or safe – were subject to “spin”. Read the article.

Scroll to Top